CPIX — Q2 2026 Financial Report Analysis

Cumberland Pharmaceuticals' second quarter of 2026 is the last one in which it was a drug-selling company. The Nashville drugmaker agreed on April 22 to sell all six of its FDA-approved brands (Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol and Vibativ) plus its interest in Talicia to Apotex for $100 million in cash, and the deal closed on July 1, the day after the quarter ended. Because of that, the 10-Q moves the whole branded business into "discontinued operations" (an accounting bucket for a business that has been sold, shown on one line so readers can see what the remaining company looks like). What's left is a clinical-stage company built around one experimental drug, ifetroban, and the quarter's numbers mostly describe a business that no longer belongs to Cumberland.

At a glance

• $8.8 million total revenue, down 18.8% from $10.8 million a year ago. Excluding Talicia, which Cumberland only began shipping in October 2025, the older brands sold $6.2 million versus $10.3 million, a 40% drop in the quarter before they were handed over.
• $4.28 million net loss (–$0.29 a share), versus a $0.74 million loss (–$0.05) a year earlier. The company that remains, with no products, lost $3.10 million; the brands being sold, which earned $2.26 million in Q2 2025, lost $1.17 million.
• $3.9 million of cash on June 30, then $100 million arrived on July 1. $22.5 million of it went straight back to shareholders as a $1.50-a-share special dividend paid July 31.

Results

Revenue in the first line is the total the company disclosed in its revenue note (Note 3), not the income statement's top line. Under the sale accounting, the income statement only shows $0.17 million of "continuing" revenue, mostly lab-space rent at the Cumberland Emerging Technologies (CET) research center. Using that figure would make the quarter look like a 98% revenue collapse, which isn't what happened.

Takeaway: Q2 matters less for what it earned than for what it shows about the timing of the sale. In the quarter before handover, the legacy brands' sales fell about 40% while selling costs rose 27%, so Cumberland sold a shrinking business for $100 million. That's more than three times what the assets were carried at on its own books (about $26 million net). What shareholders now hold is roughly $80 million of cash, before taxes and deal costs, plus one drug candidate, ifetroban, that has not yet started a Phase 3 trial.

What happened to the branded business

The quarter's main operating story is a sharp decline in the older brands, offset only partly by Talicia, an H. pylori treatment (a stomach-infection therapy) that Cumberland began promoting nationally in February 2026 under a co-commercialization deal with RedHill Biopharma:

The 10-Q does not explain the brand-level declines for this quarter; it only points readers to the revenue note. The first-half picture is a little better for Sancuso ($4.75 million vs $4.08 million, so Q1 was strong and Q2 weak) and worse for Kristalose ($2.04 million vs $5.38 million). Costs inside the sold business went the other way: selling and marketing rose to $5.37 million from $4.22 million, which the Q1 10-Q put down mainly to the cost of adding Talicia, and amortization (the write-down of what Cumberland paid for its acquired brands, spread over time) rose to $1.29 million from $1.00 million. As a result, the branded business went from earning $2.26 million a year ago to losing $1.17 million.

What the headline numbers hide

• The press release and the 10-Q disagree on Q2. The August 4 earnings release put the quarter's net loss at $4.11 million and the loss from discontinued operations at $1.01 million. The 10-Q filed three days later shows $4.27 million and $1.17 million. The $0.16 million difference matches an "other expense" line ($160,728) in the 10-Q's discontinued-operations note, and the Q1 10-Q's $3.29 million loss plus the 10-Q's Q2 figure equals the six-month total both documents report. We use the 10-Q. The release's non-GAAP reconciliation also doesn't add up per share for Q2 2025 (an adjusted loss of $2.99 million on 15.0 million shares is about $0.20 a share, not the $0.13 printed).
• The "adjusted" figures exclude very little. Adjusted loss (continuing operations, excluding interest, tax, depreciation and stock compensation) was $3.05 million, against a GAAP continuing loss of $3.10 million. Adjustments don't flatter the result.
• Cash flow: the sold brands were still producing cash, but the rest of the company wasn't. For the half year, continuing operations used $2.6 million of operating cash, while the discontinued business provided $3.2 million. Total operating cash flow was just $0.56 million, down from $4.72 million in H1 2025. Cash also covered $5.24 million to pay off the Pinnacle Bank credit line on June 29 and $1.75 million for an "investment in manufacturing", which is why cash fell to $3.9 million.
• The negative working capital is an accounting artefact. Working capital (short-term assets minus short-term bills) was –$1.6 million, and –$11.8 million for continuing operations alone. The 10-Q explains that $14.5 million of branded inventory sits in "held for sale" assets, while Cumberland kept the related trade payables ($19.6 million of accounts payable on June 30). It also kept $13.4 million of receivables. Those bills and collections will run off over the next few quarters.
• A large one-off is coming. The company says it "expects to recognize a material pre-tax gain on the sale" in Q3 2026. On our arithmetic, the net assets sold were carried at about $26 million ($34.1 million of held-for-sale assets less $7.8 million of related liabilities) against $100 million of proceeds. Q3's GAAP profit will therefore look large and will say nothing about the ongoing business. Cumberland also holds $52.6 million of federal net operating loss carryforwards (past losses that can be used to reduce taxable income), which management's tax analysis suggests will shelter more of the gain than first expected.
• No buyback or tax effect on EPS. The share count barely moved (14.98 million vs 14.96 million weighted shares), and income tax was negligible in both years.

What's left: the ifetroban pipeline

The company Cumberland now is consists of ifetroban, a drug that blocks thromboxane (a molecule involved in blood clotting, inflammation and scarring), tested in four Phase 2 programs, plus its majority stake in CET:

• Duchenne muscular dystrophy (DMD) heart disease: this is the lead program. Cumberland reported Phase 2 FIGHT DMD results in February 2025, has submitted the clinical study report to the FDA and has "begun interactions to determine the remaining regulatory requirements". In June it presented biomarker data that it describes as consistent with protection of heart muscle. The program holds Orphan Drug, Rare Pediatric Disease and Fast Track designations.
• Cancer metastasis (with Vanderbilt): a small Phase 2 met its safety goal. On the secondary efficacy endpoint, distant metastasis occurred in 3 of 18 ifetroban patients (17%) versus 5 of 10 on placebo (50%), with p=0.09, which does not reach statistical significance. Deaths from metastatic disease were 0 vs 3 (p=0.037). With 28 patients, this result is a signal worth testing again, not evidence that the drug works.
• Systemic sclerosis: enrollment is complete and top-line results are the next milestone. Idiopathic pulmonary fibrosis: still enrolling, and interim efficacy results are the next milestone.

Continuing operations cost about $3.3 million a quarter in Q2 (R&D $0.77 million, general and administrative $2.55 million). Management says its cash will fund operations and development "for at least the twelve months" after the filing. At today's spending that is a long runway. A Phase 3 trial in DMD would cost far more than the current $0.8 million a quarter of continuing R&D, though, and the 10-Q gives no cost estimate or timeline for one.

Outlook

Cumberland gives no financial guidance. The Board also authorized a new buyback of up to $5 million (replacing the old program, which had $2.1 million left) and said several directors will set up plans to buy shares.

Our read: the investment case has changed from "a small specialty pharma company with shrinking brands" to "a cash-backed bet on ifetroban". After the $22.5 million dividend, cash per share looks roughly in the low-to-mid $5 range before taxes, deal costs and settling the retained payables (our estimate: about $3.9 million plus $100 million, less $22.5 million, over 15.0 million shares, and not a company figure). Most of the stock's value therefore rests on that cash. The Q3 10-Q, expected around early-to-mid November 2026, will show the actual gain on sale, the actual post-deal cash balance and the first clean quarter of a company without products. It is the first point at which the cash burn can be judged properly. Beyond that, what to watch is the FDA's answer on what DMD still needs (whether a Phase 3 trial is required, and how large) and the systemic sclerosis top-line data. If those don't come through, this becomes a company spending its sale proceeds on overhead.